Peter O'Donnell, ACT's Brussels Correspondent

Pressure grows for advances in drug development.

Increased public engagement leads recent change in EMA profile.

The European Union has at last agreed on how HTA should be coordinated among Europe's multiple HTA agencies, bringing to an end a three-year process of discussion.

European authorities have announced a proposal for a framework to support not-for-profit organizations and academia in repurposing authorized medicines.

A new straw has appeared in the wind that may mean something more substantial will emerge than the customary rhetoric...

A proposal to address inequities in access to critical COVID vaccine commodities is still deadlocked a year after it was submitted.

The EU is offering some $13 million for advice on bringing to the market medicines that combat antimicrobial resistance—and there's only one month to claim the grant...and then nine to do the work.

Pandemic sparks new advancements in clinical trial development.

Slovenia brings EU health officials together for increased emphasis on repurposing.

Promises of "more equitable access for those with severe diseases," "decision-making flexibility where it counts," and more in a bid to win post-Brexit business.

European Commission proposes new bio-defense preparedness plan.

A draft report from parliament's cancer committee highlights the benefits that precision and personalized medicine offer.

Not just COVID is changing the landscape of pharmaceutical policy in Europe.

Allegedly more than 4,000 clinical trials of medicines are missing results on the European trial registry, in violation of transparency rules.

A new report from the EMA and EUnetHTA shows a shift towards a more efficient form of collaboration.

Conclusions from the Global Health Summit provide plenty of support for research, innovation, investment, and incentivization.

A major international collaboration within ICH features big hitters from across the world's major regulatory authorities and drug firms

The EU Cancer Research Summit sparked powerful support for personalized and precision medicine across three specific areas of research: translational, clinical, and outcomes.

Pressure mounts in Brussels as calls for new ways to debate pharma policies come from all directions.

Parliament's health committee is answering calls for a firmer grip on policies affecting the well-being of its 450 million citizens.

European Group on Ethics in Science and New Technologies issues cautious opinion on the use of gene editing amidst COVID vaccination controversy.

Rate of adoption in Europe for advanced diagnostics is falling behind that of others' globally.

A new partnership, to be known as EP PerMed, aims to bring public and private sector interests together.

Upcoming study reveals challenges faced by Europe over the pricing of pharmaceuticals.

The latest initiative against COVID, the European Health Emergency Preparedness and Response Authority, is taking shape with intentions of revealing the vulnerabilities in global supply chains and more.

After three years, member states of the EU have yet to make any real progress on legislation that would coordinate their clinical assessments more closely.

Cancer still a primary focus of EMA in light of COVID and vaccine development.

The $4 billion program will embrace the disease's entire pathway, from prevention to quality of life of patients and survivors.

After issuing a conditional marketing authorization issued just a week ago for the Moderna vaccine and receiving applications for more, the EU has reserved vaccines sufficient to treat more than 80% of the European population.